Predictive Oncology Inc.
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 16 institutions reported holding Predictive Oncology Inc. in their 13F filings, up 2 from Q1 2024. 5 opened new positions and 3 sold out. The largest holders were Vanguard Group Inc. ($74K), Geode Capital Management, LLC ($43K) and UBS Group AG ($37K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Predictive Oncology Inc.
- CUSIP
- 74039M309
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $87K |
| Exits | 3 | $308K |
All 13F filers, Q1 2024 → Q2 2024: 133,386 shares bought and 193,078 shares sold, net −59,692 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Vanguard Group Inc. | 0.00% | Reduce -50.3% | 71,307 | $74K |
| Geode Capital Management, LLC | 0.00% | Add +8.9% | 40,932 | $43K |
| UBS Group AG | 0.00% | Add +2715.8% | 35,564 | $37K |
| HRT Financial LP | 0.00% | New | 31,923 | $33K |
| Jane Street Group, LLC | 0.00% | New | 25,689 | $27K |
| Renaissance Technologies | 0.00% | Add +43.7% | 24,676 | $26K |
| State Street Corp. | 0.00% | No change | 13,837 | $14K |
| Susquehanna International Group, LLP | 0.00% | New | 13,607 | $14K |
| Citadel Advisors | 0.00% | New | 12,737 | $13K |
| Carnegie Mellon University | 0.01% | No change | 10,358 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +122.1% | 5,964 | $6K |
| Wells Fargo & Company | 0.00% | Add +3025.0% | 1,000 | $1K |
| Osaic Holdings, Inc. | 0.00% | Reduce -10.5% | 425 | $441 |
| PSI Advisors, LLC | 0.00% | No change | 399 | $415 |
| National Bank of Canada | 0.00% | No change | 100 | $102 |
| Bank of America Corp. | 0.00% | New | 33 | $34 |
"% of holder's portfolio" is PREDICTIVE ONCOLOGY INC's weight in each manager's 13F, not the share of Predictive Oncology Inc. the manager owns.